Developer docs
API playgroundTry for free, no card

Search company profiles

Pheno.AI

Full company profile

uuid0007bhd

Namestring
Pheno.AI
Legal namestring
Pheno.AI
Websiteurl
pheno.ai
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI health prediction, digital twin healthcare, biotechnology AI analytics, predictive health modeling, multi-omics data analysis
Industry1 code
PRIMARYHDAAAGAI
Healthcare & Wellness Personalization
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming Services7371
Product category
AI Health Prediction Analytics
Social media profiles1 record
Cost components4 values
Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pheno.AI develops and commercializes an AI-powered digital twin model that predicts diseases before symptoms emerge by analyzing multi-layered health data — including continuous glucose monitor data, gut microbiome, diet, physical activity, and genetic information — across 17 body systems. The technology is grounded in the Human Phenotype Project, a large-scale data initiative involving 30,000+ registered participants, and is being commercialized in partnership with the Weizmann Institute of Science.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Identifies early signs of diabetes that standard tests may miss
+1 more record
Product overview1 text field

Pheno.AI is associated with the Human Phenotype Project (HPP), which gathers extensive medical data from individuals for predictive health analysis. The source webpage is a minimal contact page with no detailed product or service information available.

Product and service2 records
1AI-Powered Digital Twin Health Prediction Model
CategoryAI Health Prediction Analytics
2Human Phenotype Project (HPP) Data
CategoryHealth Data and Research
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Weizmann Institute of Science researchers developed the AI-powered digital twin model underlying Pheno.AI's technology. The project is based on the Human Phenotype Project that gathered extensive medical data from over 13,000 individuals. Pheno.AI appears to be commercializing this research technology. The partnership involves co-development of predictive health technology with findings published in Nature Medicine.

2Human Phenotype Project Participants
Strategic tierCoreTypeOthers
Description

Over 30,000 registered participants contribute health data to the Human Phenotype Project, which forms the data foundation for Pheno.AI's digital twin model. These individuals provide multi-layered health data including wearable sensor data, genetic information, microbiome data, and continuous glucose monitoring data.

ynetnews.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ZOE runs a large-scale nutrition and metabolic health study combining CGM, microbiome, and dietary data with AI-driven personalized insights. It is the closest commercial analog to Pheno.AI's multi-omics, consumer-facing health prediction approach.

TypeDirect peer
Description

Owkin applies AI to multimodal clinical and biological data to predict disease outcomes and treatment response. It is a comparable health-AI platform leveraging large federated datasets.

3Tempus Labs
TypeBroad incumbent
Description

Tempus is a leading AI-driven precision medicine company applying large-scale multi-modal data (genomics, clinical, imaging) to disease prediction and treatment. It is a broader incumbent targeting overlapping health-AI use cases.

4GRAIL
TypeBroad incumbent
Description

GRAIL uses large-scale genomic and clinical data plus AI for early multi-cancer detection. It is a relevant comparator for the 'predict disease before symptoms' use case that Pheno.AI pursues.

TypeDirect peer
Description

Insitro applies machine learning to large phenotypic and multi-omics datasets for drug discovery and disease prediction. It shares Pheno.AI's foundational approach of combining AI with deep human phenotype data.

6K Health
TypeEmerging player
Description

K Health applies AI to large patient datasets for personalized clinical predictions and virtual primary care. It is a comparable AI-driven predictive health player with a consumer/clinical hybrid model.

TypeDirect peer
Description

Levels builds a CGM-centric metabolic health platform that uses continuous glucose data to predict and explain individual health responses. It overlaps directly with Pheno.AI's CGM-based disease prediction layer.

TypeBroad incumbent
Description

An Alphabet-owned health-AI company building multi-omics platforms (e.g., Baseline study) and wearable-driven health prediction tools. It is a well-capitalized incumbent operating in overlapping territory.

TypeEmerging player
Description

BioAge uses AI on multi-omics and clinical datasets to discover therapeutics targeting aging biology. It shares Pheno.AI's biological-age-based predictive framing and multi-omics methodology.

TypeEmerging player
Description

Sano combines genetic testing with longitudinal phenotype data and AI-driven insights for personalized health. It overlaps with the genetic and phenotype-prediction dimensions of Pheno.AI's model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pheno.AI

AI Health Prediction Analyticspheno.ai

Pheno.AI firmographics

Firmographics
Name
Pheno.AI
Legal name
Pheno.AI
Website
https://pheno.ai
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Pheno.AI industry classification

Industry
Product category
AI Health Prediction Analytics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHDAAAGAI
Healthcare & Wellness Personalization

Keywords

  • AI health prediction
  • Digital twin healthcare
  • Biotechnology AI analytics
  • Predictive health modeling
  • Multi-omics data analysis

Where Pheno.AI is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Pheno.AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Operations, Infrastructure, Marketing or Sales

Pheno.AI product offering

Product offering

Core offering

Pheno.AI develops and commercializes an AI-powered digital twin model that predicts diseases before symptoms emerge by analyzing multi-layered health data — including continuous glucose monitor data, gut microbiome, diet, physical activity, and genetic information — across 17 body systems. The technology is grounded in the Human Phenotype Project, a large-scale data initiative involving 30,000+ registered participants, and is being commercialized in partnership with the Weizmann Institute of Science.

Product overview

Pheno.AI is associated with the Human Phenotype Project (HPP), which gathers extensive medical data from individuals for predictive health analysis. The source webpage is a minimal contact page with no detailed product or service information available.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-Powered Digital Twin Health Prediction Model
  • Human Phenotype Project (HPP) Data

Quantifiable outcome

  • Identifies early signs of diabetes that standard tests may miss
  • +1 more outcomes

Companies that use Pheno.AI

Customer profile

Segments2 records

Ideal customer profiles2 records

Pheno.AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Pheno.AI partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Weizmann Institute of SciencecoreStrategic or Co-development PartnerWeizmann Institute of Science researchers developed the AI-powered digital twin model underlying Pheno.AI's technology. The project is based on the Human Phenotype Project that gathered extensive medical data from over 13,000 individuals. Pheno.AI appears to be commercializing this research technology. The partnership involves co-development of predictive health technology with findings published in Nature Medicine.
  • Human Phenotype Project ParticipantscoreOthersOver 30,000 registered participants contribute health data to the Human Phenotype Project, which forms the data foundation for Pheno.AI's digital twin model. These individuals provide multi-layered health data including wearable sensor data, genetic information, microbiome data, and continuous glucose monitoring data.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Pheno.AI competitors and assessment

Company assessment

Direct peers

  • ZOE: ZOE runs a large-scale nutrition and metabolic health study combining CGM, microbiome, and dietary data with AI-driven personalized insights. It is the closest commercial analog to Pheno.AI's multi-omics, consumer-facing health prediction approach.
  • Owkin: Owkin applies AI to multimodal clinical and biological data to predict disease outcomes and treatment response. It is a comparable health-AI platform leveraging large federated datasets.
  • Insitro: Insitro applies machine learning to large phenotypic and multi-omics datasets for drug discovery and disease prediction. It shares Pheno.AI's foundational approach of combining AI with deep human phenotype data.
  • Levels Health: Levels builds a CGM-centric metabolic health platform that uses continuous glucose data to predict and explain individual health responses. It overlaps directly with Pheno.AI's CGM-based disease prediction layer.

Broad incumbents

  • Tempus Labs: Tempus is a leading AI-driven precision medicine company applying large-scale multi-modal data (genomics, clinical, imaging) to disease prediction and treatment. It is a broader incumbent targeting overlapping health-AI use cases.
  • GRAIL: GRAIL uses large-scale genomic and clinical data plus AI for early multi-cancer detection. It is a relevant comparator for the 'predict disease before symptoms' use case that Pheno.AI pursues.
  • Verily Life Sciences: An Alphabet-owned health-AI company building multi-omics platforms (e.g., Baseline study) and wearable-driven health prediction tools. It is a well-capitalized incumbent operating in overlapping territory.

Emerging players

  • K Health: K Health applies AI to large patient datasets for personalized clinical predictions and virtual primary care. It is a comparable AI-driven predictive health player with a consumer/clinical hybrid model.
  • BioAge Labs: BioAge uses AI on multi-omics and clinical datasets to discover therapeutics targeting aging biology. It shares Pheno.AI's biological-age-based predictive framing and multi-omics methodology.
  • Sano Genetics: Sano combines genetic testing with longitudinal phenotype data and AI-driven insights for personalized health. It overlaps with the genetic and phenotype-prediction dimensions of Pheno.AI's model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Pheno.AI social profiles

Digital presence

Pheno.AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pheno.AI leadership team

Management profile

Number of profiles

Pheno.AI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pheno.AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pheno.AI

What does Pheno.AI do?

Pheno.AI develops and commercializes an AI-powered digital twin model that predicts diseases before symptoms emerge by analyzing multi-layered health data — including continuous glucose monitor data, gut microbiome, diet, physical activity, and genetic information — across 17 body systems. The technology is grounded in the Human Phenotype Project, a large-scale data initiative involving 30,000+ registered participants, and is being commercialized in partnership with the Weizmann Institute of Science.

Is Pheno.AI a public or private company?

Pheno.AI is a private company. It is classified as unknown and is currently operating.

When was Pheno.AI founded?

Pheno.AI was founded in 2022. It employs 11 to 50 people.

Where is Pheno.AI based?

Pheno.AI is headquartered in New York, United States, in the North America region.

Who are Pheno.AI's main competitors?

Direct peers on record are ZOE, Owkin, Insitro and Levels Health. Broad incumbents are Tempus Labs, GRAIL and Verily Life Sciences. Emerging players are K Health, BioAge Labs and Sano Genetics.

Does Pheno.AI have an API?

No public API is recorded for Pheno.AI.

What industry is Pheno.AI in?

Pheno.AI's product category is AI Health Prediction Analytics. Its primary akta.pro industry code is HDAAAGAI, Healthcare & Wellness Personalization. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales